Corporate News

• 
  Beilu Pharmaceutical has been awarded "Beijing Advanced Unit of Adverse Drug Reactions Daily Monitoring" for 4 consecutive years.

  2022/08/04

  Recently, the Beijing Municipal Drug Administration and Beijing Municipal Health Commission issued the "notice on the outstanding Performance of units and individuals in the monitoring of adverse...

  VIEW_MORE
• 
  Beilu's Iopamidol Injection Won the Bid for China's Pharmaceutical Centralized Procurement

  2022/07/15

  On July 12, 2022, Beilu participated in the seventh batch of national centralized drug procurement organized by the National Organization for Centralized Drug Procurement and Use Joint Procurement Off...

  VIEW_MORE
• 
  Beilu Pharma's Gadobutrol Injection Has Been Approved By NMPA

  2022/04/08

  Beijing Beilu Pharmaceutical Co., Ltd. (300016) announced today that Gadobutrol injection has obtained the "Drug Registration Certificate" issued by the NMPA（National Medial Production Administr...

  VIEW_MORE
• 
  Beilu Pharma Invested 192 Million Yuan In Cangzhou Raw Material Production Project

  2022/03/22

  The integration of "APIs + Injection" is the key layout of Beilu Pharma (300016)'s strategic development in recent years, and the construction of contrast agent APIs is one of the compan...

  VIEW_MORE
• 
  Beilu Pharma's Iopamidol Injection passed the Consistency Evaluation of Generic Drugs!

  2022/02/18

  Recently, Beilu Pharma received the “Approval Notice for Supplementary Drug Application” for two specifications of Iopamidol Injection issued by the NMPA (Notice No.: 2022B00641, 2022B00642). Follow...

  VIEW_MORE
• 
  New Specifications of Repaglinide Tablets from Beilu Pharma Were Deemed to Have Passed the Generic Drugs Quality and Efficacy Consistency Evaluation

  2021/12/20

  Now, our company received the Notification of Approval of Supplementary Application for Repaglinide Tablets issued by the State Medical Products Administration (Notification No. : 2021 B04618). After ...

  VIEW_MORE
• 
  109 Million! Subsidiary Hichi Pharmaceutical Completed a New Round of Financing to Help Increase Profitability

  2021/12/02

  To further promote the development of the company's main business and enhance the company's competitiveness, Zhejiang Hichi Pharmaceutical Co., Ltd., its holding subsidiary, launched a new ...

  VIEW_MORE